Thermo Fisher Scientific Inc. $TMO is Franklin Street Advisors Inc. NC’s 8th Largest Position

Franklin Street Advisors Inc. NC boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 541.7% during the 3rd quarter, Holdings Channel reports. The firm owned 104,094 shares of the medical research company’s stock after acquiring an additional 87,872 shares during the quarter. Thermo Fisher Scientific comprises approximately 2.9% of Franklin Street Advisors Inc. NC’s investment portfolio, making the stock its 8th largest position. Franklin Street Advisors Inc. NC’s holdings in Thermo Fisher Scientific were worth $50,488,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Revolve Wealth Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after buying an additional 20 shares during the last quarter. Lafayette Investments Inc. grew its stake in Thermo Fisher Scientific by 2.4% during the 2nd quarter. Lafayette Investments Inc. now owns 927 shares of the medical research company’s stock valued at $376,000 after purchasing an additional 22 shares during the last quarter. Challenger Wealth Management increased its holdings in shares of Thermo Fisher Scientific by 3.1% in the second quarter. Challenger Wealth Management now owns 735 shares of the medical research company’s stock valued at $298,000 after purchasing an additional 22 shares during the period. Security National Bank of Sioux City Iowa IA raised its stake in shares of Thermo Fisher Scientific by 0.3% in the second quarter. Security National Bank of Sioux City Iowa IA now owns 6,549 shares of the medical research company’s stock worth $2,655,000 after purchasing an additional 22 shares during the last quarter. Finally, Armstrong Advisory Group Inc. lifted its holdings in shares of Thermo Fisher Scientific by 2.3% during the third quarter. Armstrong Advisory Group Inc. now owns 1,039 shares of the medical research company’s stock worth $504,000 after purchasing an additional 23 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.8%

TMO stock opened at $567.01 on Friday. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $610.97. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The firm has a market cap of $213.03 billion, a P/E ratio of 32.76, a PEG ratio of 4.17 and a beta of 0.90. The company’s 50-day simple moving average is $569.01 and its 200-day simple moving average is $496.72.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. During the same quarter in the prior year, the firm posted $5.28 EPS. Thermo Fisher Scientific’s quarterly revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific announced that its Board of Directors has initiated a share buyback program on Thursday, November 6th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 2.4% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s board of directors believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.94%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 10,225 shares of the company’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $571.62, for a total transaction of $5,844,814.50. Following the completion of the transaction, the vice president directly owned 14,145 shares in the company, valued at approximately $8,085,564.90. This represents a 41.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 17,104 shares of Thermo Fisher Scientific stock in a transaction dated Friday, October 24th. The shares were sold at an average price of $573.54, for a total transaction of $9,809,828.16. Following the completion of the sale, the chief executive officer owned 113,762 shares in the company, valued at approximately $65,247,057.48. This trade represents a 13.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 149,271 shares of company stock valued at $86,507,282 in the last three months. Company insiders own 0.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on TMO. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. Argus raised their target price on shares of Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday, October 23rd. Citigroup upgraded Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $580.00 to $660.00 in a research note on Thursday, December 11th. Finally, Cowen restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $616.60.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.